WO1998013054A1 - A method for producing an extract from valeriana officinalis containing high levels of valerenic acid - Google Patents

A method for producing an extract from valeriana officinalis containing high levels of valerenic acid Download PDF

Info

Publication number
WO1998013054A1
WO1998013054A1 PCT/GB1997/002559 GB9702559W WO9813054A1 WO 1998013054 A1 WO1998013054 A1 WO 1998013054A1 GB 9702559 W GB9702559 W GB 9702559W WO 9813054 A1 WO9813054 A1 WO 9813054A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
valerenic acid
carbon dioxide
extraction
psi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1997/002559
Other languages
French (fr)
Inventor
Gary William Wheatley
Thomas Brian Chapman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Essential Nutrition Ltd
Original Assignee
Essential Nutrition Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essential Nutrition Ltd filed Critical Essential Nutrition Ltd
Priority to AU43120/97A priority Critical patent/AU4312097A/en
Priority to JP51537398A priority patent/JP3540326B2/en
Priority to DE69720234T priority patent/DE69720234T2/en
Priority to EP97941095A priority patent/EP0932409B1/en
Priority to AT97941095T priority patent/ATE235246T1/en
Publication of WO1998013054A1 publication Critical patent/WO1998013054A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/84Valerianaceae (Valerian family), e.g. valerian
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Definitions

  • This invention relates to a novel extract from the root of Valerian officinalis that contains high levels of the compound valerenic acid. Valerenic acid ' exhibits sedative activity in standard animal models. The invention also relates to a method of producing such an extract.
  • Valerian root has been traditionally used as a herbal medicine with mild tranquillismg and sedative actions. Unlike most traditional herbal medicines there is sufficient evidence of safety and efficacy for Valerian root and preparations derived therefrom to be the subject to an official monograph in the current editions of both the British Pharmacopoeia and the European Pharmacopoeia.
  • valepotriates are insoluble in watei and are not present in aqueous or alcoholic extracts of Vale ⁇ on root.
  • valerenic acid a terpenic constituent of the essential oil
  • valerenic acid and valepotriates The structure of valerenic acid and the valepotriates is provided below:
  • Liquid carbon dioxide has a high selectivity, being able to solubilise low mola mass compounds of moderate polarity whilst leaving behind in the matrix higher molecular weight lipids, waxes and pigments which would otherwise increase the bulk of an extract and dilute the actives content.
  • Liquid carbon dioxide is also superior to non-polar organic solvents m that it is non-flammable, so that the solvent can be safely vented to the atmosphere avoiding waste disposal and recycling costs.
  • the intrinsically non-toxic and highly volatile nature of carbon dioxide avoids any problems of elimination of residual levels of harmful solvents from ⁇ he product.
  • a method of preparation of an extract containing valerenic acid comprises the step of extraction of Valerian root with liquid carbon dioxide and allowing the carbon dioxide to evaporate from the resultant mixture.
  • an extract from Valerian root containing an amount of more than 4%, preferably more than 10% by weight of valerenic acid, the extract not containing any residual non- hydroxylic solvent.
  • the resultant residual extract contains a higher percentage of valerenic acid than may be obtained by solvent extraction using aqueous alcoholic mixtures.
  • the extract also exhibits in vivo sedative activity.
  • a cosolvent may be employed for example a polar hydroxylic solvent such as a C, to C 4 alcohol, preferably ethanol .
  • An amount of cosolvent of 5 to 20%, preferably 10% by weight may be employed.
  • Preferred methods involve extraction at a pressure 1400 to 4000 psi (96 to 276 bars) preferably 1500 psi (100 bars) may be employed.
  • pressure of 1400 to 4000 psi preferably 1400 to 1500 psi at a temperature of 20 to 40°C is preferred.
  • Preferred methods in accordance with this invention do not employ a cosolvent as this has been found to give proportions of valerenic acid greater than 10%.
  • Roughly ground Valerian root was packed into a suitable pressured vessel.
  • a volume of liquid carbon dioxide at the ratio of approximately 10 ml of liquid carbon dioxide per 1 g of herb was allowed to pass through the raw material at a flow rate of approximately 2 ml/min.
  • the liquid carbon dioxide was then collected, the pressure released and carbon dioxide allowed to vent to the atmosphere. Removal of any added cosolvent or residual moisture was completed by drying in a vacuum desiccator.
  • the residual extract in the collection vessel was an oil or semi-solid depending on the exact extraction conditions.
  • valerenic acid content was determined by an HPLC method based on that of R Hansel & J Schulz, Guide Apotheker Science, 122, 215 - 219 (1982).

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of preparation of an extract containing valerenic acid comprising the step of extraction of Valerian root with liquid carbon dioxide and allowing the carbon dioxide to evaporate from the resultant mixture.

Description

A METHOD FOR PRODUCING AN EXTRACT FROM VALERIANA OFFICINALIS CONTAINING HIGH LEVELS OF VALERENIC ACID
This invention relates to a novel extract from the root of Valerian officinalis that contains high levels of the compound valerenic acid. Valerenic acid 'exhibits sedative activity in standard animal models. The invention also relates to a method of producing such an extract.
Valerian root has been traditionally used as a herbal medicine with mild tranquillismg and sedative actions. Unlike most traditional herbal medicines there is sufficient evidence of safety and efficacy for Valerian root and preparations derived therefrom to be the subject to an official monograph in the current editions of both the British Pharmacopoeia and the European Pharmacopoeia.
Early scientific opinion held that the essential oil was responsible for the pharmacological actions of Valerian. However the class of epoxy mdoid esters known as valepotriates were discovered in the 1960s and it was subsequently discovered that these compounds exhibited sedative activity. However valepotriates are insoluble in watei and are not present in aqueous or alcoholic extracts of Valeπon root.
The observation that the sedative activity of Valerian root could not be completely accounted for by the presence of the valepotriates stimulated further research and more recently the importance of valerenic acid, a terpenic constituent of the essential oil, has been recognised. Several studies have confirmed the sedative action of this compound in both standard animal models and in enzyme inhibition studies related to key neurochemical pathways. The central role of valerenic acid has been acknowledged by major European manufacturer of pharmacopoeial grade Valerian extract who now standardise their products by reference to the content of valerenic acid or total sesquiterpenes . The official thin layer chromatographic method described in the British Pharmacopoeia for the analysis of Valerian stresses the importance of the presence of both the valepotπates and valerenic acid. The structure of valerenic acid and the valepotriates is provided below:
Figure imgf000004_0001
A<-e.R-E jvc.
Figure imgf000004_0002
In recent years extraction using liquified carbon dioxide has been applied to production of fractions rich in biologically active compounds, particularly terpenoids, from plant based raw materials.
Liquid carbon dioxide has a high selectivity, being able to solubilise low mola mass compounds of moderate polarity whilst leaving behind in the matrix higher molecular weight lipids, waxes and pigments which would otherwise increase the bulk of an extract and dilute the actives content. Liquid carbon dioxide is also superior to non-polar organic solvents m that it is non-flammable, so that the solvent can be safely vented to the atmosphere avoiding waste disposal and recycling costs. The intrinsically non-toxic and highly volatile nature of carbon dioxide avoids any problems of elimination of residual levels of harmful solvents from \ he product.
According to a first aspect of the present invention a method of preparation of an extract containing valerenic acid comprises the step of extraction of Valerian root with liquid carbon dioxide and allowing the carbon dioxide to evaporate from the resultant mixture.
According to a second aspect of the present invention there is provided an extract from Valerian root containing an amount of more than 4%, preferably more than 10% by weight of valerenic acid, the extract not containing any residual non- hydroxylic solvent.
The resultant residual extract contains a higher percentage of valerenic acid than may be obtained by solvent extraction using aqueous alcoholic mixtures. The extract also exhibits in vivo sedative activity.
A cosolvent may be employed for example a polar hydroxylic solvent such as a C, to C4 alcohol, preferably ethanol . An amount of cosolvent of 5 to 20%, preferably 10% by weight may be employed.
Preferred methods involve extraction at a pressure 1400 to 4000 psi (96 to 276 bars) preferably 1500 psi (100 bars) may be employed.
Use of pressure of 1400 to 4000 psi, preferably 1400 to 1500 psi at a temperature of 20 to 40°C is preferred.
Preferred methods in accordance with this invention do not employ a cosolvent as this has been found to give proportions of valerenic acid greater than 10%.
The invention is further described by means of example but not in any limitative sense.
Example
Roughly ground Valerian root was packed into a suitable pressured vessel. A volume of liquid carbon dioxide at the ratio of approximately 10 ml of liquid carbon dioxide per 1 g of herb was allowed to pass through the raw material at a flow rate of approximately 2 ml/min. The liquid carbon dioxide was then collected, the pressure released and carbon dioxide allowed to vent to the atmosphere. Removal of any added cosolvent or residual moisture was completed by drying in a vacuum desiccator. The residual extract in the collection vessel was an oil or semi-solid depending on the exact extraction conditions.
The following range of extraction conditions were employed : SAMPLE PRESSURE TEMP COSOLVENT % YIELD % VALERENIC ACID
Val 1 1500 psi 25 ° C none 1.1% 10.5%w/w
Val 2 1440 psi 36°C none 1.0% 10.8%
Val 3 1500 psi 25°C 10% 4.5% 5.3% ethanol
Val 4 4000 psi 36% none 1.0% 10.8%
The valerenic acid content was determined by an HPLC method based on that of R Hansel & J Schulz, Deutsche Apotheker Zeitung, 122, 215 - 219 (1982).
Sub-critical liquid C02 (25°C/1500 psi) liquid C02 close to the critical temp (36°C/1440 psi) and supercritical C02 significantly above the critical temperature (36°C/4000 psi) all gave products containing useful proportions of valerenic acid .
The addition of 10% ethanol cosolvent has been found to increase the overall yield of extract but significantly decreased the content of valerenic acid as other more polar compounds were also extracted.

Claims

1. A method of preparation of an extract containing valerenic acid comprising the step of extraction of Valerian root with liquid carbon dioxide and allowing the carbon dioxide to evaporate from the resultant mixture.
2. A method as claimed in claim 1, wherein the Valerian root is extracted with a mixture of liquid carbon dioxide and a polar hydroxylic solvent.
3. A method as claimed in claim 2, wherein the polar hydroxylic solvent is a C, - C., alcohol.
4. A method as claimed in claim 3, wherein the alcohol is ethanol.
5. A method as claimed in any of claims 2 to 4, wherein the amount of solvent is 5 to 20% by weight.
6. A method as claimed in claim 5, wherein the amount of cosolvent is 10% by weight.
7. A method as claimed m any preceding claim, wherein the extraction is carried out at a pressure of 1400 to 4000 psi .
8. A method as claimed in claim 7, wherein the extraction is carried out at a pressure of 1500 psi.
9. A method as claimed in any preceding claim wherein the extraction is carried out at a tempeϊθture of 20 to 40°C.
10. An extract from Valerian root containing an amount of more than 4% by weight of valerenic acid, the extract not containing any residual non-hydroxylic solvent.
11. An extract as claimed in claim 10 containing more than 10% by weight of valerenic acid.
PCT/GB1997/002559 1996-09-28 1997-09-19 A method for producing an extract from valeriana officinalis containing high levels of valerenic acid Ceased WO1998013054A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU43120/97A AU4312097A (en) 1996-09-28 1997-09-19 A method for producing an extract from valeriana officinalis containing high levels of valerenic acid
JP51537398A JP3540326B2 (en) 1996-09-28 1997-09-19 Method for producing an extract from Valeriana officinalis containing high concentrations of valeric acid
DE69720234T DE69720234T2 (en) 1996-09-28 1997-09-19 METHOD FOR PRODUCING A VALERIANA OFFICINALIS EXTRACT HIGH IN VALERIC ACID
EP97941095A EP0932409B1 (en) 1996-09-28 1997-09-19 A method for producing an extract from valeriana officinalis containing high levels of valerenic acid
AT97941095T ATE235246T1 (en) 1996-09-28 1997-09-19 METHOD FOR PRODUCING A VALERIANA OFFICINALIS EXTRACT WITH HIGH VALERENIC ACID CONTENT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9620291.6 1996-09-28
GBGB9620291.6A GB9620291D0 (en) 1996-09-28 1996-09-28 A method for producing an extract from valerian officinalis containing high levels of valerenic acid

Publications (1)

Publication Number Publication Date
WO1998013054A1 true WO1998013054A1 (en) 1998-04-02

Family

ID=10800669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002559 Ceased WO1998013054A1 (en) 1996-09-28 1997-09-19 A method for producing an extract from valeriana officinalis containing high levels of valerenic acid

Country Status (7)

Country Link
EP (1) EP0932409B1 (en)
JP (1) JP3540326B2 (en)
AT (1) ATE235246T1 (en)
AU (1) AU4312097A (en)
DE (1) DE69720234T2 (en)
GB (1) GB9620291D0 (en)
WO (1) WO1998013054A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110882239A (en) * 2018-09-10 2020-03-17 武汉联合药业有限责任公司 Analgesic use of terpene lactones
CN110882241A (en) * 2018-09-10 2020-03-17 武汉联合药业有限责任公司 Application of terpene lactone compound in improving gastric mucosa injury
CN110882243A (en) * 2018-09-10 2020-03-17 武汉联合药业有限责任公司 Sedative use of terpene lactones
CN110882242A (en) * 2018-09-10 2020-03-17 武汉联合药业有限责任公司 Use of terpene lactones for improving small intestine dyskinesia
CN119613250A (en) * 2024-12-25 2025-03-14 吉林省神经精神病医院制药厂 Valenic acid and extraction method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110882244B (en) * 2018-09-10 2022-07-12 武汉联合药业有限责任公司 Use of terpene lactones for ameliorating gastric motility disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1001776A6 (en) * 1988-06-08 1990-03-06 Pharma Trenker S A Lab Valerian extract-based formulations with sedative action

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1001776A6 (en) * 1988-06-08 1990-03-06 Pharma Trenker S A Lab Valerian extract-based formulations with sedative action

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M MORVAI-VITÁNYI ET AL.: "ANALYSIS OF SUPERCRITICAL FLUID EXTRACTS OF VALERIAN ROOTS BY COMBINED CHROMATOGRAPHY/MASS SPECTROMETRY", ACTA HORTICULTURAE, no. 344, 1993, pages 386 - 403, XP002052194 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110882239A (en) * 2018-09-10 2020-03-17 武汉联合药业有限责任公司 Analgesic use of terpene lactones
CN110882241A (en) * 2018-09-10 2020-03-17 武汉联合药业有限责任公司 Application of terpene lactone compound in improving gastric mucosa injury
CN110882243A (en) * 2018-09-10 2020-03-17 武汉联合药业有限责任公司 Sedative use of terpene lactones
CN110882242A (en) * 2018-09-10 2020-03-17 武汉联合药业有限责任公司 Use of terpene lactones for improving small intestine dyskinesia
CN110882242B (en) * 2018-09-10 2022-07-08 武汉联合药业有限责任公司 Application of terpene lactone compounds in improving small intestine dyskinesia
CN110882241B (en) * 2018-09-10 2022-07-12 武汉联合药业有限责任公司 Application of terpene lactone compound in improving gastric mucosa injury
CN110882239B (en) * 2018-09-10 2022-07-12 武汉联合药业有限责任公司 Analgesic use of terpene lactones
CN110882243B (en) * 2018-09-10 2022-07-12 武汉联合药业有限责任公司 Sedative use of terpene lactones
CN119613250A (en) * 2024-12-25 2025-03-14 吉林省神经精神病医院制药厂 Valenic acid and extraction method thereof

Also Published As

Publication number Publication date
EP0932409B1 (en) 2003-03-26
AU4312097A (en) 1998-04-17
ATE235246T1 (en) 2003-04-15
EP0932409A1 (en) 1999-08-04
GB9620291D0 (en) 1996-11-13
DE69720234D1 (en) 2003-04-30
JP3540326B2 (en) 2004-07-07
JP2001500889A (en) 2001-01-23
DE69720234T2 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
US5466451A (en) Pharmaceutically active composition extracted from tanacetum parthenium, process for its extraction, and pharmaceutical composition containing same
KR20050025588A (en) An hydroxytyrosol-rich composition from olive vegetation water and method of use thereof
EP0692257A1 (en) Process of preparation of poor pesticide active principles concentrates from plants
US5384121A (en) Method for the extraction of sesquiterpene lactones
EA030607B1 (en) Process for making extracts of plants of the scrophulariaceae family of the genus picrorhiza and use thereof for prevention and treatment of diseases caused by dna viruses
ES2227048T3 (en) METHOD FOR REMOVING OLEAGINOUS SUBSTANCES FROM SPORTS OF GANODERMA LUCIDUM.
KR20170129132A (en) Method for Producing Extract of Plant Origin Substrate Using Non-ionic Amphipathic Compound as Extraction Adjuvant in Aqueous Media
EP0932409B1 (en) A method for producing an extract from valeriana officinalis containing high levels of valerenic acid
US20190022159A1 (en) Novel method for preparing purified extracts of harpagophytum procumbens
NO328245B1 (en) Extracts of Tanacetum parthenium and pharmaceutical and cosmetic compositions containing the extracts.
AU3677589A (en) Pharmaceutical product having epidermial regenerative activity based on the active ingredient of mimosa tenuiflora and process for its obtention
WO1998030201A1 (en) Use of shogaols and gingerols for preparing deodorant compositions
US9603885B2 (en) Picrorhiza extract for prevention, elimination and treatment of infection diseases
JP3016807B2 (en) How to remove pesticides from ginseng root
Osuntokun et al. Bio-activity and Spectral Analysis of Gas Chromatography/Mass Spectroscopy (GCMS) Profile of Crude Spondiasmonbin Extracts
EP0943006B1 (en) A method for producing an extract from ganoderma lucidum containing ganoderic acid
EP3466936A1 (en) Processes for extracting cynaropicrin from leaves of cynara cardunculus l.
US6197307B1 (en) Method for producing high activity extracts from harpagophytum procumbens
GB2317613A (en) A method for producing an extract from paeonia containing high levels of paeoniflorin
US7074436B2 (en) Method for the production of phyllanthus extracts
GB2317612A (en) An extract containing artemesinin
GB2335919A (en) A method of producing high anti-inflammatory activity extracts from harpagophytum procumbens
IE61572B1 (en) Camomile oils having a high natural poly-ynes content and process for their preparation
JPH05255046A (en) Medical cosmetic
US4061739A (en) Isolation of utero-evacuant substances from plant extracts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997941095

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 515373

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09269597

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997941095

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1997941095

Country of ref document: EP